&Partners Raises Stake in SPDR S&P Biotech ETF (NYSEARCA:XBI)

&Partners boosted its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report ) by 8.4% during the 2nd quarter, Holdings Channel reports. The fund owned 5,939 shares of the exchange traded fund’s stock after acquiring an additional 460 shares during the quarter. &Partners’ holdings in SPDR S&P Biotech ETF were worth $551,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. MN Wealth Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 4.0% in the second quarter. MN Wealth Advisors LLC now owns 12,946 shares of the exchange traded fund’s stock valued at $1,200,000 after purchasing an additional 500 shares in the last quarter. Boothe Investment Group Inc. acquired a new stake in shares of SPDR S&P Biotech ETF in the second quarter valued at about $6,018,000. SOL Capital Management CO grew its position in shares of SPDR S&P Biotech ETF by 0.5% in the second quarter. SOL Capital Management CO now owns 31,940 shares of the exchange traded fund’s stock worth $2,961,000 after acquiring an additional 174 shares during the last quarter. Koa Wealth Management LLC grew its position in shares of SPDR S&P Biotech ETF by 2.4% in the second quarter. Koa Wealth Management LLC now owns 10,084 shares of the exchange traded fund’s stock worth $935,000 after acquiring an additional 232 shares during the last quarter. Finally, Atria Wealth Solutions Inc. boosted its holdings in shares of SPDR S&P Biotech ETF by 56.1% in the second quarter. Atria Wealth Solutions Inc. now owns 16,597 shares of the exchange traded fund’s stock valued at $1,539,000 after acquiring an additional 5,962 shares during the period.

SPDR S&P Biotech ETF Price Performance

Shares of XBI stock opened at $101.54 on Friday. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52. The company has a market cap of $7.74 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The company has a fifty day moving average price of $95.91 and a 200 day moving average price of $93.10.

SPDR S&P Biotech ETF Profile

(Free report)

The SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. S&P TMI tracks all US common stocks listed on the New York Stock Exchange, the American Stock Exchange, the National Automated Quotation Market of the National Association of Securities Dealers (NASDAQ) and the NASDAQ Small Cap exchanges.

Featured stories

Want to see what other hedge funds own XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).

Get daily news and ratings for the SPDR S&P Biotech ETF – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com’s FREE daily email newsletter.